Clinical Trials Logo

Filter by:
NCT ID: NCT03789708 Active, not recruiting - Clinical trials for Kidney Failure, Chronic

Effects of Gum Arabic Supplementation in Hemodialysis Patients

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

Gum Arabic is a naturally produced gummy exudate from Acacia Senegal tree. It's a complex polysaccharide with proven prebiotic properties. Through its effect on intestinal bacteria, it's expected to reduce systemic levels of toxic bacterial metabolites and reduce inflammatory markers.By increasing fecal bacteria mass it's also expected to reduce blood urea level. These changes are potentially beneficial to hemodialysis patients who suffer from disturbed intestinal flora and a chronic inflammatory status. The investigators hypothesize that supplementing the diet of hemodialysis patients with Gum Arabic for four weeks would reduce inflammatory markers, increase total anti-oxidant capacity and reduce blood urea concentration.

NCT ID: NCT03789006 Recruiting - Clinical trials for Kidney Transplant Rejection

Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation

Start date: March 21, 2018
Phase: Phase 4
Study type: Interventional

Kidney transplantation is the best available treatment option for patients with end stage renal disease. However, kidney transplantation requires life-long use of immunosuppressive medication. Because of the high cost of these medications we need to carefully evaluate the cost-effectiveness of each drug regimen, especially in low-middle income countries. The objective of this clinical trial is to compare the efficiency and cost of two immunosuppressive protocols after living donor kidney transplantation: (1) antithymocyte globulin, tacrolimus, azathioprine and prednisolone versus (2) basiliximab, tacrolimus, mycophenolate mofetil and prednisolone.

NCT ID: NCT03399955 Recruiting - Clinical trials for PKDL - Post-Kala-Azar Dermal Leishmanioid

Short Course Regimens for Treatment of PKDL (Sudan)

Start date: May 9, 2018
Phase: Phase 2
Study type: Interventional

This is an open label, randomized non comparative phase II clinical trial conducted on parallel groups, to assess the safety and efficacy of the combination of Paromomycin (20 mg/kg/d) IM for 14 days and Miltefosine (allometric dosing) oral for 42 days, and a combination of AmBisome® (20 mg/kg total dose) IV over 7 days and Miltefosine oral for 28 days (allometric dosing) for the treatment of PKDL patients in Sudan.

NCT ID: NCT03268733 Recruiting - Clinical trials for Polycystic Ovary Syndrome

The Effects of Folic Acid on Sudanese Women With Polycystic Ovary Syndrome

FolicacidPCOS
Start date: September 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

An open clinical trial

NCT ID: NCT03231449 Active, not recruiting - Stroke Clinical Trials

A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa

FEVRIER
Start date: February 1, 2017
Phase:
Study type: Observational

FEVRIER study is an observatory of hospitalizations in cardiology units in sub-Saharan Africa.

NCT ID: NCT03214692 Enrolling by invitation - Clinical trials for End-Stage Renal Disease

Gum Arabic as Antioxidant and Anti-inflammatory in Hemodialysis Patients

GA&CRF
Start date: July 2017
Phase: N/A
Study type: Interventional

Oxidative processes increased in patients with renal failure and especially patients with end stage renal failure on dialysis. Oxidative stress plays a role in renal damage and also on cardiovascular disease, atherosclerosis, which can accelerate renal damage. Gum Arabic is claimed to have antioxidant effect and this will decrease the harmful effect of the free radical on patient on hemodialysis. In this study investigators are aiming to see the effect of Gum Arabic on Oxidative Stress and inflammatory markers in patients on regular hemodialysis.

NCT ID: NCT03138044 Recruiting - Clinical trials for Hepatocellular Carcinoma

Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma

Start date: May 20, 2017
Phase: N/A
Study type: Interventional

Assessment of the long-term outcome of combined ipsilateral liver lobe devascularization (ILAD) and alcohol injection of the large hepatocellular carcinoma (HCC): single center non-randomized trial.

NCT ID: NCT03138031 Completed - Clinical trials for Hepatocellular Carcinoma Non-resectable

Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma

Start date: May 1, 2017
Phase: N/A
Study type: Interventional

Assessment of the long-term outcome of percutaneous ethanol alcohol injection (PEI) for the large and unresectable hepatocellular carcinoma: single center non-randomized trial.

NCT ID: NCT03129685 Recruiting - Clinical trials for Hepatocellular Carcinoma

Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma

NRU
Start date: May 20, 2017
Phase: N/A
Study type: Interventional

Assessment of short-term outcomes of ipsilateral lobe arterial devascularization of the large hepatocellular carcinoma: single center non-randomized trial.

NCT ID: NCT03129646 Recruiting - Clinical trials for Visceral Leishmaniasis

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Start date: January 24, 2018
Phase: Phase 3
Study type: Interventional

This is an open label, Phase III, randomized, controlled, parallel arm multicentre non-inferiority clinical trial to compare the efficacy and safety of two combination regimens of Miltefosine and Paromomycin with the standard SSG-PM for the treatment of primary adult and children VL patients in Eastern Africa.